In Allyson J. Ocean’s phase I-II clinical trial [33], patients with a prior diagnosis of Gilbert’s disease, an inherited disorder that results in impaired hepatic metabolism due to a deficiency of the enzyme UGT1A1, leading to the accumulation of bilirubin and other components, as in the present case, were excluded. This evidence concerns the gene UGT1A1 and Gilbert syndrome.